Barclays
FLGT icon

Barclays’s Fulgent Genetics FLGT Stock Holding History

Barclays’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$664K Sell
32,346
-108,665
-77% -$1.84M ﹤0.01% 3050
2026
Q1 		$2.24M Sell
141,011
-31,275
-18% -$679K ﹤0.01% 2290
2025
Q4 		$4.53M Sell
172,286
-6,581
-4% -$171K ﹤0.01% 2297
2025
Q3 		$4.04M Sell
178,867
-18,712
-9% -$385K ﹤0.01% 2359
2025
Q2 		$3.93M Buy
197,579
+5,581
+3% +$109K ﹤0.01% 2324
2025
Q1 		$3.24M Buy
191,998
+11,601
+6% +$198K ﹤0.01% 2266
2024
Q4 		$3.33M Buy
180,397
+5,542
+3% +$108K ﹤0.01% 2502
2024
Q3 		$3.8M Buy
174,855
+32,250
+23% +$721K ﹤0.01% 2310
2024
Q2 		$2.8M Sell
142,605
-8,536
-6% -$178K ﹤0.01% 1899
2024
Q1 		$3.28M Buy
151,141
+101,607
+205% +$2.52M ﹤0.01% 2156
2023
Q4 		$1.43M Buy
49,534
+35,904
+263% +$961K ﹤0.01% 3175
2023
Q3 		$364K Buy
13,630
+910
+7% +$31.1K ﹤0.01% 2979
2023
Q2 		$471K Sell
12,720
-907
-7% -$31.6K ﹤0.01% 2789
2023
Q1 		$425K Buy
13,627
+3,765
+38% +$121K ﹤0.01% 3377
2022
Q4 		$294K Buy
9,862
+4,552
+86% +$163K ﹤0.01% 3636
2022
Q3 		$203K Sell
5,310
-5,475
-51% -$274K ﹤0.01% 3197
2022
Q2 		$589K Sell
10,785
-9,253
-46% -$509K ﹤0.01% 2752
2022
Q1 		$1.25M Sell
20,038
-8,642
-30% -$569K ﹤0.01% 2227
2021
Q4 		$2.88M Buy
28,680
+8,393
+41% +$738K ﹤0.01% 2125
2021
Q3 		$1.82M Buy
20,287
+7,924
+64% +$720K ﹤0.01% 2416
2021
Q2 		$1.14M Sell
12,363
-6,216
-33% -$496K ﹤0.01% 2573
2021
Q1 		$1.79M Buy
18,579
+3,910
+27% +$404K ﹤0.01% 2377
2020
Q4 		$764K Buy
14,669
+1,204
+9% +$50.3K ﹤0.01% 2951
2020
Q3 		$540K Buy
13,465
+8,116
+152% +$254K ﹤0.01% 3178
2020
Q2 		$85K Buy
+5,349
New +$81.9K ﹤0.01% 4621
2017
Q3 		– Sell
-4,800
Closed -$31K – 6903
2017
Q2 		$31K Buy
4,800
+3,778
+370% +$30.5K ﹤0.01% 5591
2017
Q1 		$11K Buy
1,022
+920
+902% +$10.9K ﹤0.01% 6041
2016
Q4 		$1K Buy
+102
New +$963 ﹤0.01% 6453

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's FLGT Position: Q2 2026 in Review

Barclays reduced its Fulgent Genetics (FLGT) stake by 77% in Q2 2026, selling an estimated $1.84M and leaving 32,346 shares worth $664K. The position accounts for ﹤0.01% of the portfolio, ranked #3050.

Barclays first reported a position in FLGT in Q4 2016 and has held it in 28 quarters since. The position peaked at $4.53M in Q4 2025. 141 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Barclays held 32,346 shares of Fulgent Genetics worth $664K as of Q2 2026.
  • Barclays sold 108,665 Fulgent Genetics shares in Q2 2026, an estimated $1.84M.
  • Fulgent Genetics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3050 holding.
  • Barclays first reported a position in Fulgent Genetics in Q4 2016 and has held it in 28 quarters since.
  • Barclays's Fulgent Genetics position peaked at $4.53M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.